Toggle light / dark theme

Edward Alexander Bouchet Yale College class of 1874Edward Alexander Bouchet (September 15, 1852 – October 28, 1918) was an African American physicist and educator and was the first African-American to earn a Ph.D. from any American university, completing his dissertation in physics at Yale in 1876. While completing his studies, Bouchet was also the first African American to be inducted in to Phi Beta Kappa for his stellar academic performance in his undergraduate studies. Bouchet’s original research focused on geometrical optics, and he wrote a dissertation entitled “On Measuring Refractive Indices.”

Unfortunately, after completing his dissertation, Bouchet was unable to find a university teaching position after college, probably because of racial discrimination. Bouchet moved to Philadelphia in 1876 and took a position at the Philadelphia’s Institute for Colored Youth (now Cheyney University of Pennsylvania), where he taught physics and chemistry for the next 26 years. Bouchet spent the next several years in several different teaching positions around the country. In 1916, Bouchet returned home to New Haven in poor health, and died in 1918 at age 66.

Dr. Bouchet’s impact on physics still resonates today around the world. The American Physical Society (APS Physics) confers the Edward A. Bouchet Award on some of the nation’s outstanding physicists for their contribution to physics. The Edward Bouchet Abdus Salam Institute was founded in 1988 by the late Nobel Laureate, Professor Abdus Salam under the direction of the founding Chairman Charles S. Brown. In 2005, Yale and Howard University founded the Edward A. Bouchet Graduate Honor Society in his name.

I’ve been reading Scientific American for over 40 years, and it’s always giving me a good overview of topics that I’m unfamiliar with. I have come across a few recent articles on the topic of Banning Killer Robots. Here are web links to two excellent articles:

https://www.scientificamerican.com/my-account/login/?s=1


Nations racing to acquire weapons that choose their own targets are ignoring the apocalyptic scenarios that can unfold when rivals catch up.

Evolutionary Medicine — Linking human pathology with our past, present, and future evolutionary trajectories — ideaXme (http://radioideaxme.com/) welcomes Prof. Dr. Frank Rühli, Director of the Institute of Evolutionary Medicine, University of Zurich — #Ideaxme #EvolutionaryMedicine #Evolution #Microevolution #Paleopathology #BiologicalAnthropology #ComparativeAnatomy #Mummies #Mummy #Hypercholesterinemia #Diabetes #DrugAddiction #Health #Wellness #Regeneration #Longevity #Aging #IraPastor #Bioquark #Regenerage


Ira Pastor, ideaXme exponential health ambassador, interviews Professor Dr. Frank Rühli, Director of the Institute of Evolutionary Medicine and on the Medical Faculty of University of Zurich, and Founding Director, Chair, Full Professor of Evolutionary Medicine.

Ira Pastor Comments

Well, it’s a good thing, but not what I was hoping for. 3 gene therapies though Church is otherwise testing 45. But this is not the rejuvenation I was getting optimistic about. Still, I’m sure as I am getting older that I will be grateful when a treatment comes my way for something when I am elderly. But frankly this was overhyped from the start and I was part of that equation spreading a “2025” figure for some time.


Gene Therapy.

An ‘anti-aging’ gene therapy trial in dogs begins, and Rejuvenate Bio hopes humans will be next.

The startup, spun out of George Church’s lab, has tested an experimental therapy that treats four age-related diseases in mice.

Drugmaker Johnson & Johnson is “pretty confident” that it can create a vaccine to combat the deadly coronavirus, an exec said Monday.

Paul Stoffels, the company’s chief scientific officer, said it began working on a vaccine two weeks ago — and is hopeful that it can be developed within months, CNBC reported.

“We have dozens of scientists working on this so we’re pretty confident we can get something made that will work and stay active for the longer term,” Stoffels told CNBC’s “Squawk Box.”